The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Official Title: A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Study ID: NCT01922102
Brief Summary: This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)
Detailed Description: This was a phase III, multi-center, randomized, double-masked, active-controlled study comparing 0.5 mg ranibizumab vs. vPDT therapy. The study included 15 scheduled visits over 12 months, and there were to be two additional visits (2a, 3a) for subset of patients in whom PK analysis were performed. There were 3 periods in this study: Screening period-from Day -14 to Baseline; Treatment period-from Baseline to Month 11; Follow-up period-from Month 11 to Month 12 Patients entered the 11 months Treatment period at Visit 2 (Day 1) if eligibility criteria were met and were randomized in three treatment groups Group I ranibizumab 0.5 mg driven by VA stability criteria or Group II ranibizumab 0.5 mg driven by disease activity criteria or Group III vPDT (randomization ratio of 2:2:1) and received first treatment of either a ranibizumab injection and sham vPDT or sham injection and active vPDT and will return to the clinical center within 7 days to undergo safety assessments as well as assessments of the effect of treatment by the evaluating investigator. The following visits were performed at one month intervals starting at Visit 4 and continuing through Visit 14. At all monthly visits (at/from Month 2 for group I, at/from Month 1 for group II and at/from Month 3 for group III) the decision for treatment were made by the evaluating investigator based on the VA stability criteria and on the disease activity criteria. At Month 3 (visit 6) and at all following monthly visits for all three groups one of the three options can recommended by evaluating investigator: a) ranibizumab 0.5 mg, b) ranibizumab 0.5 mg + vPDT; c) vPDT. The treating investigator were then perform treatment based on randomization and masking requirements. At each monthly visit, patients had a safety evaluation by the evaluating investigator prior to study treatment, consisting of visual acuity measurements, ophthalmic examinations and evaluation of adverse events and vital signs. Routine hematology, chemistry, and urinalysis profiles were obtained at Visit 6, 9 and 12 (Month 3, 6 and 9). At Month 12 several procedures and assessments were performed which are required at study completion visit.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Novartis Investigative Site, Beijing, Beijing, China
Novartis Investigative Site, Beijing, Beijing, China
Novartis Investigative Site, Chongqing, Chongqing, China
Novartis Investigative Site, Shantou, Guangdong, China
Novartis Investigative Site, Harbin, Heilongjiang, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Changsha, Hunan, China
Novartis Investigative Site, Changsha, Hunan, China
Novartis Investigative Site, Nanjing, Jiangsu, China
Novartis Investigative Site, Nanjing, Jiangsu, China
Novartis Investigative Site, Wu XI, Jiangsu, China
Novartis Investigative Site, Nanchang, Jiangxi, China
Novartis Investigative Site, Qingdao, Shandong, China
Novartis Investigative Site, Xi'an, Shanxi, China
Novartis Investigative Site, Chengdu, Sichuan, China
Novartis Investigative Site, Tianjin, Tianjin, China
Novartis Investigative Site, Tianjin, Tianjin, China
Novartis Investigative Site, Hangzhou, Zhejiang, China
Novartis Investigative Site, Wenzhou, Zhejiang, China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Chongqing, , China
Novartis Investigative Site, Shanghai, , China
Novartis Investigative Site, Shanghai, , China
Novartis Investigative Site, Shanghai, , China
Novartis Investigative Site, Hongkong, , Hong Kong
Novartis Investigative Site, Chandigarh, Haryana, India
Novartis Investigative Site, Bangalore, Karnataka, India
Novartis Investigative Site, Vanchiyoor, Kerala, India
Novartis Investigative Site, Bhubaneswar, Orissa, India
Novartis Investigative Site, Chennai, Tamil Nadu, India
Novartis Investigative Site, Chennai, Tamil Nadu, India
Novartis Investigative Site, Coimbatore, Tamil Nadu, India
Novartis Investigative Site, Hyderabad, Telangana, India
Novartis Investigative Site, Angamaly, , India
Novartis Investigative Site, New Delhi, , India
Novartis Investigative Site, Pusan, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Manila, Metro Manila, Philippines
Novartis Investigative Site, Manila, Metro Manila, Philippines
Novartis Investigative Site, Khon Kaen, THA, Thailand
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Chiang Mai, , Thailand
Novartis Investigative Site, Nakornphathom, , Thailand
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR